Clinical Studies of Liposome-Encapsulated Doxorubicin

References

• Szoka F C. Liposomal drug delivery: Current status and future prospects. Membrane fusion, J Wilschut, D Hoekstra. Marcel Dekker Inc., New York 1991; 845–90
   Google Scholar
• Gabizon A. Liposomal anthracyclines. Hem One Clin North Am 1994; 8: 431–50
   PubMed Web of Science ®Google Scholar
• Gabizon A, Dagan A, Goren D, Barenholz Y, Fuks Z. Liposomes as in vivo carriers of adriamycin. Reduced cardiac uptake and preserved antitumor activity. Cancer Res 1982; 42: 4734–9
   PubMed Web of Science ®Google Scholar
• Olson F, Mayhew E, Maslow D, Rustum Y, Szoka F. Characterization. toxicity, and therapeutic efficacy of adriamycin encapsulated in liposomes. Eur J Cancer Clin Oncol 1982; 18: 167–76
   PubMedGoogle Scholar
• Rahman A, White G, More N, Schein P S. Pharmacological, toxicological, and therapeutic evaluation in mice of doxorubicin entrapped in cardiolipin liposomes. Cancer Res 1985; 45: 796–803
   PubMed Web of Science ®Google Scholar
• Herman E H, Rahman A, Ferrans V J, Vick J A, Schein P S. Prevention of chronic doxorubicin cardiotoxicity in beagles by liposomal encapsulation. Cancer Res 1983; 43: 5427–32
   PubMed Web of Science ®Google Scholar
• Van Hoesel Q G, Steerenberg P A, Crommelin D J, et al. Reduced cardiotoxicity and nephrotoxicity with preservation of antitumor activity of doxorubicin entrapped in stable liposomes in the Lou/M Wsl rat. Cancer Res 1984; 44: 3698–705
   PubMed Web of Science ®Google Scholar
• Gabizon A, Meshorer A, Barenholz Y. Comparative long-term study of the toxicities of free and liposome-associated doxorubicin in mice after intravenous administration. J Natl Cancer Inst 1986; 77: 459–69
   PubMed Web of Science ®Google Scholar
• Gabizon A, Peretz T, Sulkes A, et al. Systemic administration of doxorubicin-containing liposomes in cancer patients: A phase I study. Eur J Cancer Clin Oncol 1989; 25: 1795–803
   PubMedGoogle Scholar
• Rahman A, Treat J, Roh J K, et al. A phase I clinical trial and pharmacokinetic evaluation of liposome-encapsulated doxorubicin. J Clin Oncol 1990; 8: 1093–100
   PubMed Web of Science ®Google Scholar
• Treat J, Greenspan A, Forst D, et al. Antitumor activity of liposome-encapsulated doxorubicin in advanced breast cancer: phase II study. J Natl Cancer Inst 1990; 82: 1706–10
   PubMed Web of Science ®Google Scholar
• Cowens J W, Creaven P J, Greco W R, et al. Initial clinical (phase I) trial of TLC D-99 (doxorubicin encapsulated in liposomes). Cancer Res 1993; 53: 2796–802
   PubMed Web of Science ®Google Scholar
• Pestalozzi R, Schwendener R, Sauter C. Phase I/II study of liposome-complexed mitoxantrone in patients with advanced breast cancer. Ann Oncol 1992; 3: 445–9
   PubMed Web of Science ®Google Scholar
• Woodle M C, Lasic D D. Sterically stabilized liposomes. Biochim Biophys Acta 1992; 1113: 171–99
   PubMed Web of Science ®Google Scholar
• Papahadjopoulos D, Allen T M, Gabizon A, et al. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci USA 1991; 88: 11460–4
   PubMed Web of Science ®Google Scholar
• Gabizon A, Barenholz Y, Bialer M. Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethyleneglycol-derivatized phospholipid: Pharmacokinetic studies in rodents and dogs. Pharm Res 1993; 10: 703–8
   PubMed Web of Science ®Google Scholar
• Gabizon A, Chisin R, Amselem S, et al. Pharmacokinetic and imaging studies in patients receiving a formulation of liposome-associated adriamycin. Br J Cancer 1991; 64: 1125–32
   PubMed Web of Science ®Google Scholar
• Gabizon A, Catane R, Uziely B, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 1994; 54: 987–92
   PubMed Web of Science ®Google Scholar
• Miller A B, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981; 47: 207–14
   PubMed Web of Science ®Google Scholar
• Gabizon A, Barenholz Y. Adriamycin-containing liposomes in cancer chemotherapy. Liposomes as drug carriers, G Gregoriadis. Wiley, Chichester 1988; 365–79
   Google Scholar
• Gabizon A, Sulkes A, Peretz T, . Liposome-associated doxorubicin: Preclinical pharmacology and exploratory clinical phase. Liposomes in the therapy of infectious diseases and cancer, G Lopez-Berestein, I J Fidler, et al. UCLA Symposia on Molecular and Cellular Biology (New Series), Alan Liss Inc., New York 1989; 89: 391–402
   Google Scholar
• Gabizon A, Goren D, Barenholz Y. Investigations on the antitumor efficacy of liposome-associated doxorubicin in murine tumor models. Isr J Med Sci 1988; 24: 512–7
   PubMedGoogle Scholar
• Blum R H, Carter S K. Adriamycin—A new anticancer drug with significant clinical activity. Ann Int Med 1974; 80: 249–59
   PubMed Web of Science ®Google Scholar
• Amselem S, Cohen R, Barenholz Y. In vitro tests to predict in vivo performance of liposomal dosage forms. Chem Phys Lipids 1993; 64: 219–37
   PubMed Web of Science ®Google Scholar
• Hwang K J. Liposome pharmacokinetics. Liposomes: From biophysics to therapeutics, M J Ostro. Marcel Dekker, New York 1987; 109–55
   Google Scholar
• Mayer L D, Tai L C, Bally M B, et al. Characterization of liposomal systems containing doxorubicin entrapped in response to pH gradients. Biochim Biophys Acta 1990; 1025: 143–51
   PubMed Web of Science ®Google Scholar
• Haran G, Cohen R, Bar L K, Barenholz Y. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim Biophys Acta 1993; 1151: 201–15
   PubMed Web of Science ®Google Scholar
• Gregoriadis G, Senior J. Liposomes in vivo: A relationship between stability and clearance. Targeting of drugs with synthetic systems, G Gregoriadis, J Senior, G Poste. Plenum Press, New York 1986; 183–92
   Google Scholar
• Allen T M, Chonn A. Large unilamellar liposomes with low uptake into the reticuloendothelial system. FEBS Lett 1987; 223: 42–6
   PubMed Web of Science ®Google Scholar
• Gabizon A, Papahadjopoulos D. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc Natl Acad Sci USA 1988; 85: 6949–53
   PubMed Web of Science ®Google Scholar
• Lokich J J, Moore C. Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome. Ann Int Med 1984; 101: 798–800
   PubMed Web of Science ®Google Scholar
• Samuels B L, Vogelzang N J, Ruane M, Simon M A. Continuous venous infusion of doxorubicin in advanced sarcomas. Cancer Treat Rep 1987; 71: 971–2
   PubMedGoogle Scholar
• Van de Velde C J. The staging of hepatic metastases arising from colorectal cancer. Recent Results Cancer Res 1986; 100: 85–90
   PubMedGoogle Scholar